Your browser doesn't support javascript.
Adapting Regulations Post-Brexit
Pharmaceutical Technology Europe ; 33(3):7-8, 2021.
Article in English | ProQuest Central | ID: covidwho-20239776
ABSTRACT
The UK government is taking advantage of the new regulatory flexibility, afforded by Brexit, to boost the country's competitiveness in pharma On 1 Jan. 2021, the United Kingdom formally left the European Union to become a third country and no longer a member of the Union's single market and customs union. The UK has, for example, decided to draw up its own version of the EU chemicals legislation-called REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals)-which sets technical standards for chemical ingredients for medicines (1). Because the UK is a separate legal entity-a third country-the UK's excipient producers and their raw material suppliers have started to be concerned about procedures like customs declarations and rules of origin. [...]by 18 Feb. 2021 the UK had vaccinated 26% of its population versus 8% in Denmark-the leading EU country for vaccines availability-6% in Germany, and 5% in France (6). NICE needs to change Industry believes that the National Institute for Health and Care Excellence (NICE), the government's health technology assessment (HTA) body, is being too restrictive with its evaluation of digitalization products, which ultimately sets the price paid by the government for them (9).
Keywords
Search on Google
Collection: Databases of international organizations Database: ProQuest Central Type of study: Experimental Studies / Reviews Topics: Vaccines Language: English Journal: Pharmaceutical Technology Europe Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: Databases of international organizations Database: ProQuest Central Type of study: Experimental Studies / Reviews Topics: Vaccines Language: English Journal: Pharmaceutical Technology Europe Year: 2021 Document Type: Article